| Code | CSB-RA011614MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Genakumab, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B plays a critical role in mediating inflammatory cascades by activating immune cells, inducing fever, and promoting the production of additional inflammatory mediators. Dysregulated IL1B signaling is implicated in numerous pathological conditions, including autoinflammatory disorders, rheumatoid arthritis, type 2 diabetes, atherosclerosis, and various inflammatory diseases. Elevated IL1B levels have also been associated with cancer progression, neurodegenerative conditions, and cytokine storm syndromes.
Genakumab represents an important therapeutic approach for neutralizing IL1B activity, making this biosimilar a valuable tool for investigating IL1B-mediated pathways and inflammatory mechanisms. Researchers can utilize this antibody to explore the molecular basis of IL1B signaling, evaluate potential therapeutic interventions, and study the cytokine's role in disease pathogenesis. This product supports investigations into immune regulation, inflammation research, and translational studies aimed at understanding IL1B-related disorders.
There are currently no reviews for this product.